COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

The CompassHER2 trials (COMprehensive use of Pathologic Response ASSessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and tucatinib

Protocol No
ALLIANCE-A011801
Principal Investigator
Lubna Chaudhary
Phase
III
Summary
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Description
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Participating Institutions
Drexel Town Center
Froedtert Menomonee Falls Hospital
Froedtert West Bend Hospital
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category